MeiraGTx (MGTX) Bank of America Global Healthcare Conference 2026 summary

Strategic repositioning and key achievements

• Regained global rights to RPGR (bota-vec) from J&J, considered the most significant de-risking event in the past year.

• Hologen collaboration secured full funding for the Parkinson's program.

• Achieved Breakthrough Therapy Designation (BTD) for xerostomia program.

• Senior talent from J&J joined, accelerating development and regulatory efforts.

Manufacturing and regulatory readiness

• Built vertically integrated, scalable gene therapy manufacturing over 11 years, enabling rapid IND and BLA filings.

• In-house manufacturing allows for commercial-scale material from early stages, reducing program timelines by years.

• Manufacturing infrastructure and regulatory familiarity de-risk late-stage programs and facilitate regulatory alignment.

Xerostomia pivotal program and clinical strategy

• Pivotal xerostomia study nearing completion, with BLA filing targeted for the first half of next year.

• Primary endpoint is a patient-reported outcome (XQ), with saliva flow as a key secondary endpoint.

• Study powered for success with any single dose cohort outperforming placebo; no clear dose response observed.

• Three-year durability data show sustained patient benefit, influencing prescriber and payer perceptions.

• Pricing discussions suggest a potential range of $100,000–$250,000, with focus on patient access and payer negotiations.